Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Shares of Swiss pharma giant Roche were down more than 2% in early trading today, after it revealed that second-quarter 2020 sales fell 9.6% to 14.1 billion Swiss francs ($15.20 billion). Factoring out the strength of the franc, revenue dropped 4%. 23 July 2020
Biotechnology
Adding to a major supply deal with the UK earlier this week, today Pfizer and German partner BioNTech announced an agreement with the US Department of Health and Human Services and the Department of Defense to meet the government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. 22 July 2020
Biotechnology
Shares in US biotech Biogen were up by 1.5% following 90 minutes of trading on Wednesday after the company presented its second quarter financial results. 22 July 2020
Biotechnology
Japanese drugmaker Daiichi Sankyo has teamed up with Paris-based cancer research institute Gustave Roussy in a multi-year, multi-study research collaboration. 22 July 2020
Biotechnology
The USA’s Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (OCA), from Intercept Pharmaceuticals (Nasdaq: ICPT), for the treatment of non-alcoholic steatohepatitis (NASH) with fibrosis. 22 July 2020
Biotechnology
Oral Janus kinase (JAK) inhibitor Rinvoq (upadacitinib) 15mg and 30mg, once daily monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase III study in individuals with moderate to severe atopic dermatitis. 22 July 2020
Biotechnology
The Seattle-based subsidiary of Hamburg’s Evotec will develop COVID-19 antibodies for the US Department of Defense (DoD), under an $18.2 million contract. 22 July 2020
Biotechnology
Gilead Sciences’ shares dipped 1.7% to $76.76 on Tuesday, after it announced that it will invest $300 million to acquire a 49.9% equity interest in Tizona Therapeutics, a privately held company developing first-in-class cancer immunotherapies, with the intention of buying the whole company later. 22 July 2020
Biotechnology
A new project from the European Medicines Agency (EMA) has been established to monitor the efficacy and safety of COVID-19 treatments and vaccines in everyday clinical practice. 21 July 2020
Biotechnology
Houston, USA-based CNS Pharmaceuticals has lined up both American and European manufacturers for berubicin, its lead drug candidate for the treatment of glioma brain tumors. 21 July 2020
Biotechnology
Privately-held US start-up Jnana Therapeutics has entered a strategic, multi-target collaboration and license agreement with Roche (ROG: SIX) for the discovery of small molecule drugs directed at the solute carrier (SLC) family of metabolite transporters. 21 July 2020
Biotechnology
Privately held Danish drugmakers Union Therapeutics and LEO Pharma have completed a transaction for the former to acquire the global rights to the LEO PDE4 inhibitor compound series to be re-named UNI500. 21 July 2020
Biotechnology
Connecticut company BioXcel Therapeutics closed 14% higher after Monday’s trading. 21 July 2020
Biotechnology
A novel gene therapy program developed at University College London (UCL), the first project to be supported by Apollo Therapeutics, has been licensed to healthcare investment firm Deerfield. 21 July 2020
Biotechnology
US clinical-stage biotech Pieris Pharmaceuticals has announced that its Phase I studies of PRS-343 have been placed on partial clinical hold by the US Food and Drug Administration 21 July 2020
Biotechnology
There was nothing to deter investors, governments and populations in a set of interim results from the ongoing Phase I/II COV001 trial of AZD1222, a COVID-19 vaccine candidate being developed by AstraZeneca and the University of Oxford. 20 July 2020
Biotechnology
Shares in Synairgen closed more than 400% higher on Monday. 20 July 2020
Biotechnology
China’s Antengene Corporation has successfully closed a $97 million Series C financing. 20 July 2020
Biotechnology
Having already signed up to receive 100 million of AstraZeneca and the University of Oxford’s investigational COVID-19 vaccine, the UK government has now gambled on two further candidates. 20 July 2020
Biotechnology
PTC Therapeutics today announced an agreement to monetize a portion of the risdiplam royalty stream for $650 million from Royalty Pharma, with the news bringing the firm’s shares down 2.5% to $54.29 in early trading. 20 July 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze